Ohmic Biosciences

Executive Summary

Ohmic Biosciences is a preclinical-stage biotechnology company pioneering a novel class of targeted protein degraders known as Molecular Glue Degraders (MGDs). Leveraging its proprietary Ohmic Engine platform, the company systematically discovers and optimizes small molecules that induce proximity between E3 ubiquitin ligases and disease-causing proteins, leading to their targeted degradation. This approach enables the targeting of historically undruggable proteins, with initial focus areas in oncology and immunology. Founded in 2020 and headquartered in Cambridge, MA, Ohmic is well-positioned to address significant unmet medical needs by expanding the druggable proteome. The platform’s potential to degrade previously intractable targets has attracted interest from the drug discovery community. While still in early preclinical stages, Ohmic’s technology could unlock new therapeutic avenues across multiple indications. Upcoming catalysts include the nomination of a lead development candidate, the release of in vivo proof-of-concept data, and potential partnership or financing announcements to advance the pipeline toward the clinic. The company’s disciplined approach and experienced team enhance its prospects in the competitive protein degradation space.

Upcoming Catalysts (preview)

• Q4 2025Lead candidate nomination for first MGD program75% success
• Q2 2026In vivo proof-of-concept data for oncology target60% success
• 2026Series B financing or strategic partnership70% success